Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
14:30:40 EDT Sat 13 Jun 2026
Enter Symbol
or Name
USA
CA



Q:MNOV - MEDICINOVA INC - https://www.medicinova.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
MNOV - Q1.01.12·1.290.11.23-0.05-3.9103.51126421.26  1.26  1.231.96  1.16819:47:53Jun 0815 min RT 2¢

Recent Trades - Last 10 of 642
Time ETExPriceChangeVolume
19:47:53Q1.2286-0.05144
19:03:53Q1.23-0.05300
19:03:53Q1.23-0.05189
18:38:01Q1.17-0.11500
18:37:26Q1.17-0.11500
18:35:14Q1.17-0.11500
18:17:59Q1.17-0.1110
18:13:56Q1.17-0.11113
18:02:57Q1.18-0.10514
18:02:35Q1.15-0.13115

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-06-08 08:00U:MNOVNews ReleaseMediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment
2026-05-26 19:00U:MNOVNews ReleaseMediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
2026-04-27 19:00U:MNOVNews ReleaseNew Peer-Reviewed Study Reveals Actionable Immune-Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation
2026-03-16 07:00U:MNOVNews ReleaseMediciNova to Participate at the 38th Annual ROTH Conference
2026-01-29 18:00U:MNOVNews ReleaseMediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN-166 (ibudilast) in ALS patients
2026-01-06 09:00U:MNOVNews Release2026 New Year's Greetings from the CEO
2025-12-18 06:00U:MNOVNews ReleaseMediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy
2025-12-08 06:00U:MNOVNews ReleaseMediciNova Announces Update and Basic Characteristic Randomized Patients' of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND
2025-12-01 18:00U:MNOVNews ReleaseMessage from the CEO to MediciNova Shareholders
2025-11-18 06:00U:MNOVNews ReleaseMediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor
2025-11-06 18:00U:MNOVNews ReleaseMediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards
2025-11-04 07:00U:MNOVNews ReleaseMediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
2025-10-30 19:00U:MNOVNews ReleaseMediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication
2025-10-06 08:00U:MNOVNews ReleaseMediciNova to Present at the LD Micro Main Event XIX Investor Conference
2025-09-22 08:00U:MNOVNews ReleaseMediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast)
2025-09-16 08:00U:MNOVNews ReleaseMediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND
2025-09-08 09:00U:MNOVNews ReleaseMediciNova Provides Shareholder Update on Key Developments
2025-09-03 07:00U:MNOVNews ReleaseMediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference
2025-08-26 19:00U:MNOVNews ReleaseMediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial
2025-07-31 19:30U:MNOVNews ReleaseMediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million